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TO THE EDITOR
Human eosinophils have an important
role in the pathogenesis of allergic
inﬂammatory diseases including atopic
dermatitis (AD) and allergic diseases
(Simon et al., 2004; Rothenberg and
Hogan, 2006; Raap and Wardlaw,
2008). Eosinophils secrete proinﬂam-
matory cytokines, chemokines, and
proteins like eosinophil cationic protein
(RNASE3), a protein known to correlate
with disease severity in patients with AD
(Kapp, 1993). Another cytokine cor-
relating with disease severity in patients
with AD is the pruritogenic IL-31 (Raap
et al., 2008; Raap et al., 2012). IL-31
was shown to promote chronic derma-
titis in mice through the induction of
severe itch (Dillon et al., 2004).
Findings that a subpopulation of
IL-31RA(+)/TRPV1(+)/TRAP1 (+) neurons
mediates T-helper cell–dependent itch
support the role of IL-31 in pruritus
(Cevikbas et al., 2014). In addition, skin
IL-31 mRNA expression and IL-31 serum
level correlate with Th2 cytokines includ-
ing IL-4 and IL-13 in AD and acute allergic
contact dermatitis (Neis et al., 2006; Raap
et al., 2012).
Originally, IL-31 expression was
shown in activated CD4+ T-helper cells
(Dillon et al., 2004; Cornelissen et al.,
2012). We demonstrate the expression
of IL-31 in human peripheral blood
eosinophils (Figure 1a–h). Freshly iso-
lated eosinophils from non-atopic
patients, who gave written informed
consent (approved by the ethics
committee of the Hannover Medical
School (MHH)), were cultivated with
and without IL-3, and intracellular IL-31
was measured (Figure 1a, see Supple-
mentary Material and Methods S1
online). Stimulation with IL-3, a cyto-
kine that can enhance responses of
eosinophils to various agonists (Simon
et al., 2004), increased the intra-
cellular expression of IL-31 (Figure 1a).
These results were conﬁrmed with the
western blot technique and the densito-
metric analysis of the western blot
(Figure 1b and c). In addition, we deter-
mined IL-31 protein content in super-
natants by ELISA (Figure 1d). The
release of IL-31 increased during the
time of incubation of eosinophils
(Figure 1d). Similar to the densitometric
analysis (Figure 1c) of the western
blot, IL-3 signiﬁcantly increased IL-31
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protein release (Figure 1d). Indeed this
is interesting given the fact that eosino-
phils could activate neighboring cells
including T cells, mast cells, and
epithelial cells in the inﬂammatory
inﬁltrate via the release of IL-31. Thus,
this ﬁnding is highly relevant, especially
in regard to inﬂammatory itchy skin
diseases and particular as it was shown
that IL-31-stimulated T cells produce
CCL2 and GM-CSF (Stott et al., 2013).
As IL-31 is increased in allergic
inﬂammatory skin diseases including
AD, we determined the release of IL-31
from eosinophils of AD patients, who
signed informed consent (approved by
the ethics committee of the MHH). AD
eosinophils displayed an increased
release of IL-31 after 24 hours in culture
compared with eosinophils of non-
atopic patients (Figure 1e). We thus
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Figure 1. Analysis of the expression and release of IL-31 in eosinophils. Human eosinophils from atopic dermatitis and non-atopic patients were isolated as
described in Supplementary Material and Methods (S1 online). Eosinophils were stimulated with various cytokines (each 10 ngml−1) or SEB (1 μgml−1) for the
respective time (NS: unstimulated) (*Po0.05; **Po0.01; ***Po0.001; SEM). (a) Intracellular staining of IL-31 displayed as histogram (n= 10). After 60 minutes of
stimulation, ﬁxed and permeabilized eosinophils (NA) were stained with antibodies against IL-31 or isotype. Light grey area: isotype; colourless area: no
stimulation (NS); dark grey area: IL-3 stimulation. (b) Detection of IL-31 with western blot (WB) from protein lysate 60minutes after stimulation (one WB out of
three; D1/ D2: Donor; n=3, NA). GAPDH was used as a reference gene. (c) Densitometric analysis of the WB results by using ImageJ (n=3). (d) Determination
of IL-31 in the supernatant after 24 and 48 hours by ELISA (non-stimulated, n= 8, NA). (e) Determination of IL-31 in the supernatant of eosinophils
from atopic dermatitis (non-stimulated, n=3, AD) and non-atopic (non-stimulated, n=3, NA) patients after 24 hours. (f) IL-31 intracellular staining after
stimulation with IL-4, IL-13, IL-5, and IL-31 for 60 minutes (MFI: mean of ﬂuorescence intensity; NA). (g). Determination of IL-31 in the supernatant of eosinophils
(eos, NA), ﬁbroblasts (ﬁbro), and co-culture of both after 24 hours in culture (non-stimulated, n=3). (h) Determination of IL-31 in the supernatant by ELISA.
CD4+ and CD8+ T cells, CD14+ monocytes, eosinophils (CD16−, eos), and monocyte-derived dendritic cells (DC) (MoDC, immature/ mature) were isolated
and stimulated with SEB for 6 hours (n=4, NA). AD, atopic dermatitis patient; NA, non-atopic patient.
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addressed whether Th2 cytokines regu-
late IL-31 release. Accordingly, eosino-
phils were cultivated for 60minutes with
IL-4, IL-5, IL-13, and IL-31 with subse-
quent analysis of intracellular IL-31 (see
Supplementary Material and Methods S1
online). Stimulation with Th2 cytokines
led to a clear upregulation of IL-31,
which was signiﬁcant with IL-4 and
IL-13 (Figure 1f). Interestingly, IL-31
stimulation led to an increased expres-
sion of IL-31 as well (Figure 1f).
We further analyzed the impact of a
co-culture of eosinophils with ﬁbro-
blasts in relation to their IL-31 release
(generation of ﬁbroblasts see Supple-
mentary Material and Methods S1
online) after 24 hours in culture. As
already observed, ﬁbroblasts secrete
IL-31 (Cornelissen et al., 2011).
However, the co-culture of eosinophils
and ﬁbroblasts did not further enhance
IL-31 expression (Figure 1g). As we
were interested in the expression of
IL-31 by eosinophils in comparison with
other cells, we isolated CD4+ and CD8+
T cells, CD14+ monocytes, eosinophils
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Figure 2. Chemotaxis, ROS, and CCL26 release and calcium mobilization. Human eosinophils from non-atopic patients were isolated as described in Materials
and methods and stimulated with IL-31 (1–100 ngml−1) or C5a as a positive control for the respective time (S1 online). (nAB: 20 μgml−1; anti-IL31RA Ab
10 μgml−1; anti-OSMR Ab, 10 μgml−1), (*Po0.05; **Po0.01; ***Po0.001; SEM). (a) Chemotaxis assay: migration of eosinophils during 3 hours was analyzed
by using a modiﬁed Boyden Chamber in the presence of C5a (Co, 10−8 M) and IL-31 (1–100 ngml−1) (n=15). Neutralizing antibodies against IL-31 were used to
block the migration (n= 3). Chemotactic activity is presented as the ratio of the number of migrating eosinophils in the presence of stimulus/migrating eosinophils
in the presence of the medium. Dotted line indicates the level of chemotaxis of unstimulated (NS) eosinophils. (b) Measurement of CCL26 in the supernatants after
48 hours by ELISA after stimulation with IL-3 (positive control, Co, 10 ngml−1) and IL-31 (n= 13). (c) Release of ROS (reactive oxygen species) displayed as
intensity count (n=20) measurement using a single-photon imaging system followed immediately after stimulation with C5a (Co, 10−8 M) or IL-31. (d) Calcium
inﬂux was measured immediately after stimulation with IL-31 and displayed as ﬂuorescence intensity per seconds (n=3). C5a (10−8 M), CCL11, and CCL26 (each
10 ngml−1) served as positive controls. (e) Inhibition of the IL-31 (10 ngml−1) induced calcium inﬂux by using anti-IL-31RA. (f) Measurement of the IL-31
(10 ngml−1) induced calcium inﬂux after prestimulation with anti-OSMR. Co, pos. control; nAB, neutralizing antibody; NS, non stimulated.
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(CD16− cells), and monocyte-derived
dendritic cells (MoDC; immature and
mature) and assessed the IL-31 release in
supernatants from non-stimulated and
staphylococcus enterotoxin B (SEB, 1
μgml−1)-stimulated cells after 6 hours.
SEB, an endotoxin from S.aureus, is
known to rapidly induce IL-31 mRNA
expression in atopic individuals (Sonkoly
et al., 2006). Interestingly, eosinophils
displayed the highest IL-31 release,
which was signiﬁcantly higher compared
with the IL-31 release by CD4+ T-helper
cells (Figure 1h). Furthermore, SEB led to
a clear induction of IL-31 in eosinophils
and CD4+ T-helper cells (Figure 1h).
As it seems that IL-31 has a chemo-
tactic function (Dillon et al., 2004),
we investigated whether IL-31 inﬂuences
the eosinophil chemotaxis by perform-
ing a modiﬁed Boyden-chamber assay
(Figure 2a). Within the chosen dose range
of 1–100 ngml−1, IL-31 induced signiﬁ-
cantly the chemotaxis in eosinophils in a
dose-dependent manner (Figure 2a).
Using a neutralizing anti-IL-31 antibody,
the IL-31 induced chemotaxis was com-
pletely abolished (Figure 2a). This indi-
cates that IL-31 may be involved in the
recruitment of eosinophils, which is
consistent with the ﬁnding that IL-31
induces cell surface expression of adhe-
sion molecule CD18 (Cheung et al.,
2010). As eosinophils represent circulat-
ing cells, their recruitment via chemotaxis
is important for the maintenance of the
inﬂammatory inﬁltrate (Rothenberg and
Hogan, 2006). In addition, we displayed
that IL-31 increased CCL26 release in a
dose-dependent manner, which supports
the ﬁnding that IL-31 induces migration of
eosinophils (Figure 2b). In response to a
chemoattractant, the concentration of
cytoplasmic calcium rises. We tested the
calcium inﬂux under the inﬂuence of
IL-31. In eosinophils from non-atopic
patients, the intracellular Ca2+ levels
increased after stimulation with IL-31
(Figure 2d). As positive controls C5a,
CCL11, and CCL26 were used (Lampinen
et al., 2004). IL-31 caused an inﬂux of
Ca2+ similar to CCL11 and CCL26
(Figure 2d). Further, we wanted to see
whether the Ca2+ mobilization was
mediated via these receptors by blocking
with anti-IL-31RA and anti-OSMR anti-
bodies. In the presence of antibodies, the
IL-31 induced increase in intracellular
Ca2+ level was reduced. This reduction
was more effective by blocking IL-31RA
then by blocking the OSM receptor
(Figure 2e and f). Thus, our data indicate
a biological function of IL-31 exerted via
IL-31RA in eosinophils.
Eosinophils are suggested of having a
role in tissue damage by the release of
reactive oxygen species (Neves and
Weller, 2009). Therefore, we analyzed
whether IL-31 inﬂuences the release of
reactive oxygen species of eosinophils.
Stimulation with IL-31 in a dosage of
10, 50, and 100 ngml− 1 induced a
respiratory burst of eosinophils com-
pared with the incubation in a medium
(Figure 2c). C5a was used as a positive
control and led to a release of reactive
oxygen species as expected (Figure 2c).
Summarizing, to our knowledge pre-
viously unreported, we show that eosino-
phils are a source of IL-31 and capable of
releasing it. The ﬁndings that the IL-31
release by eosinophils is higher in AD
patients and Th2 cytokines further
increase the IL-31 release in eosinophils
suggest an important regulatory pathway
for inﬂammatory skin diseases including
AD. Finally, we show that IL-31 affects
eosinophils functionally with induction
of chemotaxis, mobilization of Ca2+,
release of CCL26, and reactive oxygen
species. Thus, IL-31 constitutes an attrac-
tive target for the treatment in eosinophil-
associated allergic inﬂammatory diseases.
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